Prothea Technologies’ vision is to offer lung cancer biopsy and treatment in a single hospital visit. Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined. Prothea is developing a medical device consisting of a Microendoscope combined with an Image Processing System, which enhances visualisation by providing in situ analysis of lesion structure at a molecular level. Further R&D is planned to develop a laser ablation catheter for the treatment of lesions immediately following visualisation and biopsy. The integration of these two systems (real-time imaging and ablation) will streamline biopsy and treatment into a single hospital visit, reducing time-to-treat from weeks to minutes, thereby relieving hospital pressures and improving patient outcomes.